Outcomes and toxicities with RVD combination regimens as induction therapy
RVD indicates lenalidomide, bortezomib, and dexamethasone; D, pegylated doxorubicin; C, cyclophosphamide; P, panobinostat; V, vorinostat; PR, partial response; VGPR, very good partial response; CR, complete response; nCR, near complete response; PFS, progression-free survival; and NR, not reported.
Sign In or Create an Account